Introduction
The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established. However, the demand for kidney donor organs greatly exceeds the current supply. Long-term allograft and patient outcomes are required to determine whether the use of HCV infected organs should be considered for all patients with ESRD waiting for kidney transplant. The survival benefit of kidney transplantation for patients with end-stage renal disease (ESRD) is well established [1, 2] . However, the demand for kidney donor organs greatly exceeds the current supply which encourages organ procurement organizations and transplant centers to look for innovative strategies to increase the donor pool.
Recently, the opioid crisis has increased the number of overdose deaths exponentially [3] . Additionally, the number of hepatitis C virus (HCV) seropositive donors increased from 452 organs per year to 1506 per year between the years of 2000 and 2016 but only 57% of the HCV seropositive kidneys were transplanted in 2016 [4] . The use of hepatitis C infected donors could increase the number of kidneys available for transplantation but this strategy has historically been avoided because of risk of HCV transmission as well as inadequate treatment response and risk of rejection with interferon-based regimens. The advent of highly effective secondgeneration direct acting antivirals (DAAs) has increased viral cure of patients with chronic HCV infection to more than 96% [5] [6] [7] . Ongoing research is investigating whether DAAs can be prescribed post-transplant to HCV negative recipients receiving HCV infected donors to increase the donor pool.
The Transplanting Hepatitis C Kidneys Into Negative KidnEy
Recipients (THINKER) trial, was a prospective, open-label, nonrandomized trial that included a total of 20 kidney transplant HCV negative recipients who received hepatitis C infected kidneys, determined by HCV nucleic acid testing (NAT) [8, 9] . Recipients were included if they were expected to have prolonged times on the wait list while being maintained on dialysis. Recipients could not have any contraindications to liver transplantation or evidence of liver disease detected by FibroScan imaging or serologic testing.
Only HCV genotype 1 infected donor kidneys were included.
Patients were assessed for HCV transmission on post-op day 3 and were started on elbasvir-grazoprevir (ELB-GRZ) upon detection of HCV infection. Participants with genotype 1a HCV were tested for baseline nonstructural protein 5A (NS5A) resistance mutations.
Patients with genotype 1a/1b were treated with ELB-GRZ for a total of 12 weeks while patients with genotype 1a with NS5A resistance mutation were started on ELB-GRZ and ribavirin for 16 weeks total. Outcomes included HCV cure determined by sustained viral response at 12 weeks (SVR12) and adverse events attributable was non-genotype 1 [10] . For this reason, a second trial started, called Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV Negative Recipients (EXPANDER), to utilize these discarded organs [11] . Overall, the methodology of EXPANDER was very similar to THINKER, however, EXPANDER included kidney donor organs infected with genotype 1-4 and DAA therapy was administered as pre-and post-exposure prophylaxis. One dose of ELB-GRZ was administered pre-operatively as pre-exposure prophylaxis. After transplant, patients with genotype 1a/1b and 4 were treated with ELB-GRZ for 12 weeks total. Donors with HCV genotype 1a were tested for NS5A mutation and recipients who received a HCV genotype 1a with NS5A mutation kidney allograft were prescribed ELB-GRZ and ribavirin for 16 weeks total. Patients who received genotype 2 or 3 organs were treated with ELB-GRZ and sofosbuvir (SOF) for 12 weeks total. If the donor allograft genotype was unable to be determined due to insufficient viral load, the recipient was treated with ELB-GRZ for 12 weeks. donors. Furthermore, the use of HCV infected kidney donors for transplantation decreases the patient's wait time on dialysis [8] [9] [10] [11] [12] . Emerging evidence is addressing some of the initial concerns about the use of HCV infected donors including cost-effectiveness of this strategy [13, 14] . The study performed Molnar et al further illustrates that third-party insurance companies are paying for the therapy with approval of DAA therapy occurring in less than a week in most cases [12] .
While initial studies increase the collective understanding of managing this patient population, some questions remain unanswered [8] [9] [10] [11] [12] [13] [14] [15] [16] . First, what is the optimal timing of DAA therapy? EXPANDER was the first study to attempt pre-and postexposure DAA prophylaxis strategy [11] . While the number of patients in this study was small, less patients in EXPANDER had elevated transaminase levels compared to either THINKER or the The grades and timing of these rejections were not discussed. It is unclear whether the rejections occurred during or after DAA therapy but it should be noted that the overall incidence of ACR for this cohort is similar to national outcomes [17] . Patients received rabbit antithymocyte globulin for induction therapy with a mean total dose of 4.9 mg/kg (±0.9 mg/kg). Target tacrolimus goal levels post-transplant and goal mycophenolate mofetil doses were not noted. Future studies should continue to monitor the development of DSAs and rejection in this patient population.
Overall, the utilization of HCV infected kidneys for HCV negative recipients is a promising strategy to increase access to transplantation and should continue to be studied. Current evidence suggests that HCV negative recipients who receive pre-and postexposure DAA prophylaxis or DAA therapy upon detection of HCV transmission can be transplanted with HCV infected kidneys with no documented chronic HCV transmission to date and excellent shortterm renal outcomes. Future studies should investigate the optimal timing of DAA therapy to decrease adverse events described in the literature including the development of DSAs, CMV and BK viremia, and elevated transaminase levels. Long-term allograft and patient outcomes should also be collected to determine whether the use of HCV infected organs should be considered for all patients with ESRD waiting for kidney transplant.
